{"name":"Par Pharmaceutical, Inc.","slug":"par-pharmaceutical-inc","ticker":"","exchange":"","domain":"parpharm.com","description":"","hq":"Woodcliff Lake","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-01","label":"Demadex Phase 3 readout (Hypertension (HTN))","drug":"Demadex","drugSlug":"demadex","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":9,"colorKey":"immunology","drugs":[{"name":"Flagyl","genericName":"Flagyl","slug":"flagyl","indication":"Other","status":"marketed"},{"name":"ARAVA","genericName":"ARAVA","slug":"arava","indication":"Other","status":"marketed"},{"name":"Buspar","genericName":"Buspar","slug":"buspar","indication":"Other","status":"marketed"},{"name":"Demadex","genericName":"Demadex","slug":"demadex","indication":"Other","status":"phase_1"},{"name":"Dostinex","genericName":"Dostinex","slug":"dostinex","indication":"Hyperprolactinemia","status":"phase_1"},{"name":"Inderal-LA","genericName":"Inderal-LA","slug":"inderal-la","indication":"Other","status":"marketed"},{"name":"Monodox","genericName":"Monodox","slug":"monodox","indication":"Other","status":"marketed"},{"name":"Oxandrin","genericName":"Oxandrin","slug":"oxandrin","indication":"Catabolic Process","status":"marketed"},{"name":"Tramadol APAP","genericName":"Tramadol APAP","slug":"tramadol-apap","indication":"Other","status":"phase_1"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Buspirone HCl","genericName":"Buspirone HCl","slug":"buspirone-hcl","indication":"Generalized anxiety disorder","status":"marketed"},{"name":"Klonopin","genericName":"Klonopin","slug":"klonopin","indication":"Absence seizure","status":"marketed"},{"name":"Parnate","genericName":"Parnate","slug":"parnate","indication":"Major depressive disorder","status":"marketed"}]}],"pipeline":[{"name":"Buspirone HCl","genericName":"Buspirone HCl","slug":"buspirone-hcl","phase":"marketed","mechanism":"Buspirone acts as a serotonin 5-HT1A receptor agonist to reduce anxiety without the sedation or dependence associated with benzodiazepines.","indications":["Generalized anxiety disorder"],"catalyst":""},{"name":"Flagyl","genericName":"Flagyl","slug":"flagyl","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ARAVA","genericName":"ARAVA","slug":"arava","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Buspar","genericName":"Buspar","slug":"buspar","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Demadex","genericName":"Demadex","slug":"demadex","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Dostinex","genericName":"Dostinex","slug":"dostinex","phase":"phase_1","mechanism":"D(1B) dopamine receptor, D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A","indications":["Hyperprolactinemia","Prevention of ovarian hyperstimulation syndrome"],"catalyst":""},{"name":"Inderal-LA","genericName":"Inderal-LA","slug":"inderal-la","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Klonopin","genericName":"Klonopin","slug":"klonopin","phase":"marketed","mechanism":"GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel, GABA-A receptor; anion channel","indications":["Absence seizure","Atonic seizure","Lennox-Gastaut syndrome","Myoclonic seizure","Panic disorder"],"catalyst":""},{"name":"Monodox","genericName":"Monodox","slug":"monodox","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Oxandrin","genericName":"Oxandrin","slug":"oxandrin","phase":"marketed","mechanism":"Androgen receptor","indications":["Catabolic Process"],"catalyst":""},{"name":"Parnate","genericName":"Parnate","slug":"parnate","phase":"marketed","mechanism":"7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase, Cytochrome P450 2B6, Lysine-specific histone demethylase 1B","indications":["Major depressive disorder"],"catalyst":""},{"name":"Tramadol APAP","genericName":"Tramadol APAP","slug":"tramadol-apap","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxPNUVoS1NWMmxKZ0EtbXVmWmlibk1RUjZrMllLV2F3dFRlYXF2cjkzVVowRjEwTUU5UW9kNWZBNGxUS3VSMHlrWElZbTlpXzBEOWd5TlZTTHJsZ28wcURSWndhOG9oakxNY2lTbElmSHpXTnhLUkRLa19EVTdsVUNJcnlnUUxKQ0xJT0ZlekZ0MWxfS08zbmgwdDQzV2tjaFB1a2dtUjBVV2VHRkQ1dl9rX1MwYjBnMVJtWE90VllOYkV2Vi00ZnhDOU93Z0FEZnBJdXE2VHhqYXQyQktGdXdua1I5TFpXcGUySmVhbkJlNEE3eEE?oc=5","date":"2026-01-12","type":"pipeline","source":"PR Newswire","summary":"Par Health Names Dr. William Larkins as EVP and Chief Scientific Officer and President, Sterile Injectables - PR Newswire","headline":"Par Health Names Dr. William Larkins as EVP and Chief Scientific Officer and President, Sterile Injectables","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNT05rLVltSGItU3FXekE2bEZ4SjNtMnRUdVZ2bTRDaW9vTGZXcEhUZlduWWxOeDlKV3IyQjNYMFc2eE9xSURTbDhWQTBOckhzOUN4bWlkY3gybzZReFB2LXFTYWdzUlZJZlpJUm1YeWc3dU5NWnZwRXN4RXBWTWZFNkNYdVlseW01a3ZTV245OU1jMzhrY3NkWkktQm9RQW9IeWo0dk16amsxNGNfYTlVSTY5eHNRM3ZfaUUtSg?oc=5","date":"2025-11-11","type":"deal","source":"Fierce Pharma","summary":"With merger in the books, Mallinckrodt and Endo rebrand as Keenova and spin off Par Health - Fierce Pharma","headline":"With merger in the books, Mallinckrodt and Endo rebrand as Keenova and spin off Par Health","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxPRGVQVG5SdUdFWDhvUmgwRkFjdDdaMEdwTGVzV1dRUHFtRXh2djhtd3lOT1pFejFTOVMyOUIzZy1RZHZ6b3g3TWNjc2cta2tqNVZJVlNBcnA1eVJTTEVTbzFRbTFDT2lwWTI3bjhpYmxyNlYwOWM3M2k0SnFMaFVJNUdhbjRSTkR5a2pySERZOVZFMGx4YzhCdWs2ME5tZk9YY091Njc3LUpEZmhfSFk4QjBhM2NNRzY1N3hLdHZ0RWtLNXZGZXRtdEJEZlZ2bWUzd04yTHkwTWhmYXh2Q3VYVlM1TkJwOFE3MURvR1k5NlVjbVplSXlsN0dHcUwtbFlhOUVjcVoxMW9DRkVxSTZMNEdLOA?oc=5","date":"2025-11-10","type":"patent","source":"PR Newswire","summary":"Par Health Completes Spin-Off from Mallinckrodt, Creating an Independent Leader in Generic Pharmaceuticals and Sterile Injectables - PR Newswire","headline":"Par Health Completes Spin-Off from Mallinckrodt, Creating an Independent Leader in Generic Pharmaceuticals and Sterile I","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNam9QTFNGSkF1akVXM3N1WVFNdkR6QmhjTFRWNmdSbUllc083VS1VU3VDUV9vY1lxNzNkSjF6TW1VSXppQ2FpRTdlOGgxdUZ4WlU3cTNMSXNlZmFXRC1qSVF0a2hpdnMwZ2s1ZGs5NF85dm5pLUhCNVhCU3RYS2hvZ0lHaWNSWUdCdUxWNHJvQUVGcWN6bW5rTHdrV1FmTnBwZlBkT1J4cGZKQUQzNU9IWl9LLVI2VVBCWHQ2OThQSldIUQ?oc=5","date":"2025-11-10","type":"earnings","source":"BioSpace","summary":"Par Health Reports Third Quarter 2025 Financial Results and Provides Business Update - BioSpace","headline":"Par Health Reports Third Quarter 2025 Financial Results and Provides Business Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOZkE0c25uN2J3UjZHR2tkNHFNYUlwaE1SNm5HV2FyUVk1SUpPY3h5SEhKc0ZOMko1LVIyODNWelF2Y0FiS0I2d29kMXI0c1dObkVVV095bE9hSGNQQk5aQllqY3BMbmlqUVZva0hIdnBpUmJFUWZPMnljdWpEdUFLeEJCM0xDeWRWQ1FqRElfcVB3QU0?oc=5","date":"2024-12-22","type":"deal","source":"Contract Pharma","summary":"Par Pharmaceutical to Acquire JHP Pharmaceuticals - Contract Pharma","headline":"Par Pharmaceutical to Acquire JHP Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOOEtnVXBQNzk5Uy1zaVVZdFdMWC1aeWQxdnh3dTY2dGs2S0pmZVRCNWlIWFk1MDhPa0tQTXBUQW9qczFRZURYNGppRHhnQWdYcV9VSjdndEFiSl8wSkpwRHpYNjM0bTFpTUVIb0ZzMXI0dkNaNjhZVzdZWkJZTVR3ZTl6Yk9UcXc1VUJSdHJrYWU3NjQ2RXBDZUItTlptdno0TnhNVTNfNzlpUQ?oc=5","date":"2024-08-19","type":"pipeline","source":"Bloomberg Law News","summary":"TPG Sued for $4.5 Billion by Endo Trustee Over Par Pharma Sale - Bloomberg Law News","headline":"TPG Sued for $4.5 Billion by Endo Trustee Over Par Pharma Sale","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQMzNsbmdiY2s3WXF2Z1hqOU5KM3lVRmM5ZVN2M1Nza1lvQk9HLXNCMDMzTDFReHBPcEN5Qk8tZC1wZThqMDVETUNWRDRvNXN4RF8wU01pRldsMkthcnEtWm9jcWFwbURweWtfQU1hcy1wMDhoVENGMENNZkZTQjR0cVR0aE9mYjRyZF9TRDhPajRMZw?oc=5","date":"2021-07-02","type":"patent","source":"Generics and Biosimilars Initiative","summary":"Shire grabs Par’s attention with patent lawsuit - Generics and Biosimilars Initiative","headline":"Shire grabs Par’s attention with patent lawsuit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE1rM2g5d21WeFlCeFl0VzN5ckJvRTktbXBPNUxDeGJNckFTaEE3OHB3bXMtTUNRM3hJVWtBamFsd3NvTzR1QmpldTZaNnhDbkVxWXR3TjVyMkhWSk1kaGluLVc5SQ?oc=5","date":"2021-03-08","type":"pipeline","source":"pharmacytimes.com","summary":"Par Pharmaceutical - pharmacytimes.com","headline":"Par Pharmaceutical","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQZ19UTzBSZmVpbWQwSWQyN2xCbWg4bkxSVXhXVjJ3SW9hRThQN19KazVxOGJhR0RaZWJXVWVaeWhmT3lJQ2QtUm1ZS1pUeFpJSUl2SUlpcnhlNXdHUUFxVWdyUFVub3RsNVBrbTFBbTVaMDVDZm84OHptT1dYbFRJaHBfemQtek1q?oc=5","date":"2019-08-20","type":"pipeline","source":"SEC.gov","summary":"8.20.2019 PR - SEC.gov","headline":"8.20.2019 PR","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE45SXdVMzdZbnRQRlJ6M0lzOXpLdDFhcURqc183Sk5CUHc0NHBzTC1mbmRGUF9mYW1ycF9aR2dUMHQ3TmVpQzI5d1ZfcHU5dDZvenRlRmlRWnpEY1hlWVRzMlpoZWI5ZGgtRlZIc0RjWlg2bHV2M18tWUFadVZsQQ?oc=5","date":"2015-07-22","type":"deal","source":"Financier Worldwide","summary":"TPG backed Par Pharma sold in $8bn deal - Financier Worldwide","headline":"TPG backed Par Pharma sold in $8bn deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOQ2hueDlkbUhoR2ZQRUJPYmF5N19RbTZpVzNjZXFkNGk4dlQ0ZC1vYlV3TXdwMjVwd2JvLWo2Q0s3QkhtTWk2d3B5eTZtWGF0T3REc1UtS3pZMUptVnk3Wi1VUmU0R0VQekc1Y043VnRBanhuX1dscTJ4U3Y5bHhZWXhxVmg1TzNwdTFnYjNoY0RfczktR2MtNTNIdzNSR0k2dE9sNQ?oc=5","date":"2015-05-18","type":"deal","source":"tpg.com","summary":"Endo to Acquire Par Pharmaceutical, Strategically Expanding Generics Business to a Top 5 Industry Leader - tpg.com","headline":"Endo to Acquire Par Pharmaceutical, Strategically Expanding Generics Business to a Top 5 Industry Leader","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQNXNRZHVTUl8wdmhhYVdDRFQ1QlJ0SFFOTmp4aG1vcDZCdHJoT3JVTm02S0VpdzF5c0NoQ2FlWHpYcms0ckh2Zlk5MkdfZVY2TFF0WEtpZm5QSEdlVUhIbFh3dldVM01ZaUR5NnpwUVQ4NGdrX3FtQzNybzhJdElmVWFzcGU?oc=5","date":"2014-12-04","type":"pipeline","source":"JD Supra","summary":"Par Pharmaceutical, Inc. v. TWi Pharmaceuticals, Inc. (Fed. Cir. 2014) - JD Supra","headline":"Par Pharmaceutical, Inc. v. TWi Pharmaceuticals, Inc. (Fed. Cir. 2014)","sentiment":"neutral"}],"patents":[],"drugCount":12,"phaseCounts":{"marketed":9,"phase_1":3},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}